NCT01725126 To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes Status COMPLETED Phase PHASE2
NCT01725100 A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies Status COMPLETED Phase PHASE1
NCT01721603 Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets Status TERMINATED Phase PHASE2
NCT01721317 Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures Status TERMINATED Phase PHASE4
NCT01721135 A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval. Status WITHDRAWN Phase PHASE1
NCT01716533 Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI) Status COMPLETED Phase NA
NCT01716520 Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Status COMPLETED Phase PHASE3
NCT01716208 Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma Status COMPLETED Phase PHASE2
NCT01715792 Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK Status COMPLETED Phase N/A
NCT01711736 Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age Status COMPLETED Phase PHASE3
NCT01711723 A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment Status COMPLETED Phase PHASE1
NCT01711658 TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. Status COMPLETED Phase PHASE2
NCT01706328 A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Status COMPLETED Phase PHASE3